Journal article
The relationship between markers of antenatal iron stores and birth outcomes differs by malaria prevention regimen-a prospective cohort study
Holger W Unger, Valentina Laurita Longo, Andie Bleicher, Maria Ome-Kaius, Stephan Karl, Julie A Simpson, Amalia Karahalios, Elizabeth H Aitken, Stephen J Rogerson
BMC MEDICINE | BMC | Published : 2021
Abstract
BACKGROUND: Iron deficiency (ID) has been associated with adverse pregnancy outcomes, maternal anaemia, and altered susceptibility to infection. In Papua New Guinea (PNG), monthly treatment with sulphadoxine-pyrimethamine plus azithromycin (SPAZ) prevented low birthweight (LBW; <2500 g) through a combination of anti-malarial and non-malarial effects when compared to a single treatment with SP plus chloroquine (SPCQ) at first antenatal visit. We assessed the relationship between ID and adverse birth outcomes in women receiving SPAZ or SPCQ, and the mediating effects of malaria infection and haemoglobin levels during pregnancy. METHODS: Plasma ferritin levels measured at antenatal enrolment in..
View full abstractRelated Projects (2)
Grants
Awarded by Malaria in Pregnancy Consortium - Bill & Melinda Gates Foundation
Awarded by Pregvax Consortium (European Union's Seventh Framework Programme FP7-2007-HEALTH)
Awarded by Pfizer Inc.
Awarded by National Health and Medical Research Council of Australia
Awarded by Australian Centre of Research Excellence in Malaria Elimination (ACREME)
Funding Acknowledgements
The present study was funded by a research grant from the British Maternal and Fetal Medicine Society (BMFMS) to HWU. The parent trial was supported by the Malaria in Pregnancy Consortium (funded by the Bill & Melinda Gates Foundation, 46099), and the Pregvax Consortium (European Union's Seventh Framework Programme FP7-2007-HEALTH, PREGVAX 201588, and the Spanish Government EUROSALUD 208 Programme). Azithromycin was provided by Pfizer Inc. as part of an Investigator-Initiated Research Grant (WS394663). This work was also supported by the National Health and Medical Research Council of Australia (Investigator Grant Leadership Level 1 awarded to JA Simpson (1196068)), and the Australian Centre of Research Excellence in Malaria Elimination (ACREME) 1134989. Funding sources did not have any involvement in the study design; collection, analysis, and interpretation of data; and compilation and submission of this report.